Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix

Inclusion Criteria: * male outpatients, aged 18 or older, willing and able to provide written informed consent; * histological diagnosis of prostate carcinoma; * more than 6-month survival prospect; * no bone metastases as assessed by bone scintigraphy; * eligibility to ADT with Degarelix in the opinion of the clinical investigator. Exclusion Criteria: * patients with absolute or relative contraindication for prescription of Degarelix. In particular: * hypersensitivity towards any component of Firmagon® * patients who receive concomitant medications that might prolong the QT interval, in particular class I A (such as quinidine, procainamide, disopyramide,) or class III antiarrhythmics (such as amiodarone, sotalol, dofetilide, ibutilide) * patients with history of or risk factors for Torsades de Pointes * patients who take either methadone or moxifloxacin or antipsychotic * patients with alteration in electrolyte blood levels (such as sodium, potassium, calcium and magnesium) * patients with severe kidney and/or liver dysfunctions; * concomitant bone metabolic disease, such as Paget's disease, primary hyperparathyroidism or chronic hypercortisolism, as recorded by medical history; * renal failure (baseline serum creatinine more than 1.5 mg/dl); * prior hormonal treatment; * prior or concomitant treatment with bisphosphonates or other drugs known to affect bone metabolism (for example steroids, calcitonin); * patients participating in an interventional clinical trial in which any treatment or follow-up is mandated;